Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Longeveron Inc (LGVN)

Longeveron Inc (LGVN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,793
  • Shares Outstanding, K 21,333
  • Annual Sales, $ 2,390 K
  • Annual Income, $ -15,970 K
  • EBIT $ -22 M
  • EBITDA $ -21 M
  • 60-Month Beta 0.18
  • Price/Sales 4.91
  • Price/Cash Flow N/A
  • Price/Book 1.29
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.06
  • Most Recent Earnings $-0.39 on 11/04/25
  • Next Earnings Date 02/27/26
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.37
  • Number of Estimates 3
  • High Estimate -0.27
  • Low Estimate -0.42
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5333 +3.66%
on 12/16/25
0.6876 -19.60%
on 12/02/25
-0.1289 (-18.91%)
since 11/14/25
3-Month
0.5333 +3.66%
on 12/16/25
0.9900 -44.16%
on 10/09/25
-0.1966 (-26.23%)
since 09/16/25
52-Week
0.5333 +3.66%
on 12/16/25
2.2400 -75.32%
on 01/06/25
-1.2672 (-69.63%)
since 12/16/24

Most Recent Stories

More News
Beyond Weight Loss: The "Cellular Reset" That Could Create the Next Biotech Supercycle

Issued on behalf of Avant Technologies Inc. VANCOUVER – Baystreet.ca News Commentary – The longevity economy is entering a massive repricing event as researchers confirm that metabolic dysfunction...

LGVN : 0.5528 (+0.45%)
AVAI : 0.3177 (+0.70%)
BIOA : 12.51 (+0.40%)
GAA : 32.48 (-0.13%)
DNLI : 17.02 (-1.85%)
MAPT : 0.0003 (unch)
KLTO : 0.3900 (+2.77%)
Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum

MIAMI, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic...

LGVN : 0.5528 (+0.45%)
LGVNR : 0.0005 (-37.50%)
Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging

The patent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to patients with aging-related frailty with inflammaging and also...

LGVN : 0.5528 (+0.45%)
LGVNR : 0.0005 (-37.50%)
Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer’s Disease Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025)

Results obtained in the Phase 2 placebo-controlled CLEAR-MIND clinical trial showed that treatment with stem cell therapy laromestrocel was associated with a reduction in MRI measured neuroinflammation...

LGVN : 0.5528 (+0.45%)
LGVNR : 0.0005 (-37.50%)
Longeveron Laromestrocel Data in Alzheimer’s Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025)

MIAMI, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related...

LGVN : 0.5528 (+0.45%)
LGVNR : 0.0005 (-37.50%)
Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy

The patent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to patients with aging-related frailty with inflammaging No approved...

LGVN : 0.5528 (+0.45%)
LGVNR : 0.0005 (-37.50%)
Longeveron® Announces Third Quarter 2025 Financial Results and Provides Business Update

On track for top-line trial results in the third quarter of 2026 from pivotal Phase 2b clinical trial ELPIS II. ELPIS II is evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric...

LGVN : 0.5528 (+0.45%)
LGVNR : 0.0005 (-37.50%)
Longeveron® to Report Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025

MIAMI, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related...

LGVN : 0.5528 (+0.45%)
LGVNR : 0.0005 (-37.50%)
Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR’s BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect

Laromestrocel is a proprietary, scalable, allogeneic cellular therapy being evaluated to improve the clinical outcomes of children with HLHS Full enrollment achieved for pivotal Phase 2b clinical trial...

LGVN : 0.5528 (+0.45%)
LGVNR : 0.0005 (-37.50%)
Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

MIAMI, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related...

LGVN : 0.5528 (+0.45%)
LGVNR : 0.0005 (-37.50%)

Business Summary

Longeveron Inc. is a clinical stage biotechnology company. It engages in developing cellular therapies for chronic aging-related and life-threatening conditions. The company's investigational product includes LOMECEL-B(TM). Longeveron Inc. is based in MIAMI.

See More

Key Turning Points

3rd Resistance Point 0.6073
2nd Resistance Point 0.5886
1st Resistance Point 0.5707
Last Price 0.5528
1st Support Level 0.5341
2nd Support Level 0.5154
3rd Support Level 0.4975

See More

52-Week High 2.2400
Fibonacci 61.8% 1.5880
Fibonacci 50% 1.3866
Fibonacci 38.2% 1.1853
Last Price 0.5528
52-Week Low 0.5333

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar